Who are Zavicefta, Ceftazidime-Avibactam's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fosfomycin and imipenem, Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol, Sulopenem Etzadroxil/Probenecid, cefepime/AAI101 combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zavicefta-ceftazidime-avibactam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Zavicefta, Ceftazidime-Avibactam — Competitive Intelligence Brief

Zavicefta, Ceftazidime-Avibactam (zavicefta-ceftazidime-avibactam) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cephalosporin antibiotic and beta-lactamase inhibitor combination. Area: Infectious Disease.

marketed Cephalosporin antibiotic and beta-lactamase inhibitor combination Bacterial cell wall synthesis Infectious Disease Live · refreshed every 30 min

Target snapshot

Zavicefta, Ceftazidime-Avibactam (zavicefta-ceftazidime-avibactam) — Pfizer.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Zavicefta, Ceftazidime-Avibactam TARGET	zavicefta-ceftazidime-avibactam	Pfizer	marketed	Cephalosporin antibiotic and beta-lactamase inhibitor combination	Bacterial cell wall synthesis
Fosfomycin and imipenem	Fosfomycin and imipenem	Juan A. Arnaiz	marketed	Beta-lactam antibiotic combination	Bacterial cell wall synthesis (MurA enzyme and penicillin-binding proteins)
Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol	Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol	Tuberculosis Research Centre, India	phase 3	Anti-tuberculosis combination therapy	Multiple: DNA gyrase (moxifloxacin), mycobacterial cell wall synthesis (isoniazid, ethambutol), RNA polymerase (rifampicin), bacterial metabolism (pyrazinamide)
Sulopenem Etzadroxil/Probenecid	Sulopenem Etzadroxil/Probenecid	Iterum Therapeutics, International Limited	phase 3	carbapenem antibiotic	bacterial cell wall synthesis
cefepime/AAI101 combination	cefepime/AAI101 combination	Allecra	phase 3	beta-lactam antibiotic	bacterial cell wall synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cephalosporin antibiotic and beta-lactamase inhibitor combination class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zavicefta, Ceftazidime-Avibactam — Competitive Intelligence Brief. https://druglandscape.com/ci/zavicefta-ceftazidime-avibactam. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab